Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

By B. Dankbar, T. Padró, R. Leo, B. Feldmann, M. Kropff, R. Mesters, Hubert Serve, Wolfgang E. Berdel, J. Kienast. Blood, 2000

599 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/8ef400b2f94f531e14cef60f31b629353546028f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. J. Adams

In Molecular Biology

1. R. Jove
2. P. Richardson
3. T. Hideshima
4. W. Kuehl
5. Hua Yu
6. Robert A. Gatenby
7. L. Ellis
8. Eric B. Haura

In Oncology

1. R. Jove
2. Hua Yu
3. D. Pardoll
4. L. Ellis
5. Eric B. Haura
6. Lanxi Song
7. D. Gabrilovich
8. M. Karin

Citations in the corpus

• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007, background): “Moreover, multiple myeloma cells localized in the bone marrow milieu secrete cytokines such as TNFα, transforming growth factor-β ( TGFβ ) and VEGF, which further upregulate IL6 secretion from BMSC”
• Multiple myeloma: evolving genetic events and host interactions (2002, background): “cgi?l=7124">TNF-α ) as a result of mutual interactions that are mediated by direct cell–cell contact, cell–matrix contact or secreted factor”
• Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis (2002, background): “…et al., 1995b; Shweiki et al., 1992), or genetic alterations (Jiang et al., 2000; Pages et al., 2000; Rak et al., 1995, 2000), including activation of oncogenic tyrosine kinases (Dankbar et al., 2000; Ellis et al., 1998; Mukhopadhyay et al., 1995a; Petit et al., 1997; Wiener et al., 1999).”
• Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “IL-6 may up-regulate expression of VEGF to stimulate angiogenesis in bone marrow infiltrated MM cells (Dankbar et al., 2000).”
• Environment-mediated drug resistance: a major contributor to minimal residual disease (2009, methodology): “used patient specimens to show that fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), respectively, produced by myeloma cells induced IL-6 secretion by stromal cells, and vice vers”